Gelstat Corp (GSAC) Stock Price & Analysis
Gelstat Corp (GSAC) rose 0.00% to USD 0 as of June 10, 2026 at 03:31 UTC, according to Nexqual real-time market data.
GSAC last closed at USD 0; the session ranged USD 0–0 on volume of 3,449 shares. Market capitalization is $1.12M, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:31 UTC.
Key Statistics (as of June 10, 2026 at 03:31 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 3,449 shares |
| Market Cap | $1.12M |
| Exchange | PNK |
Technical Analysis (GSAC)
Nexqual's technical model rates GSAC "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:31 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.64 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (GSAC)
Wall Street analysts rate GSAC "None", per Nexqual as of June 10, 2026 at 03:31 UTC.
| Consensus Rating | None |
|---|
Earnings (GSAC)
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financials & Fundamentals (GSAC)
| Total Revenue | $363,533 |
|---|---|
| Revenue Growth (YoY) | +2.80% |
| Gross Margin | +70.41% |
| Operating Margin | -87.01% |
| Profit Margin | -77.96% |
| Current Ratio | 0.3 |
| Total Cash | $76,407 |
| Total Debt | $849,620 |
| Free Cash Flow | $-34,358 |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financial Health Score (GSAC)
Nexqual rates Gelstat Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:31 UTC.
| Growth | Mixed — Revenue +2.8% YoY (latest Q), slow |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $76K cash, no debt |
| Cash Flow | Weak — FCF negative: -$34K, burning cash |
| Efficiency | Mixed — No data |
Ownership (GSAC)
| Insider Ownership | +9.52% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 3.74B |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Leadership (GSAC)
Gelstat Corp is led by Javier G. Acosta, CEO & Director, per Nexqual as of June 10, 2026 at 03:31 UTC.
| CEO & Director | Javier G. Acosta |
|---|---|
| Chief Marketing Advisor | Charles F. Tarzian (age 68) |
From Gelstat Corp's Latest SEC 10-K Filing (filed 2012-10-22)
Key Strengths & Strategy (as disclosed to the SEC)
- GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products.
- Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms.
- The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GXXM | GEX Management, Inc. | USD 0.11 | ▲ 5% |
| AOXG | Aoxing Pharmaceutical Company, | USD 0 | ▼ 19.23% |
| BEGI | BlackStar Enterprise Group, Inc | USD 0 | ▲ 0% |
| LVGI | Limitless Venture Group Inc. | USD 0 | ▲ 0% |
| CCAJ | Coastal Capital Acquisition Cor | USD 0 | ▼ 15% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:31 UTC. This page is informational and not investment advice.